Asahi Kasei is consistently pursuing its strategy of building a focused, sustainable specialty pharmaceutical platform for immunocompromised and medically complex patient groups
The announcement follows a record-setting $1.2 million accelerated LineaDNA order
The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25
The pharmaceutical segment led growth, generating Rs. 337 crore in revenue, while the crop protection business contributed Rs. 157 crore
The company has commissioned a new plant at Khanna (Punjab), which has begun commercial production
Launched in August 2025, GSK India’s Oncology business is rapidly gaining momentum
The company’s EBITDA margin remained resilient above 20%
Call it one of the most striking turnarounds in the Indian pharma sector this fiscal year
Leading the showcase is FCT iStream, Fujifilm’s latest CT scanner built on a “Less is More” design philosophy
On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY
Subscribe To Our Newsletter & Stay Updated
